June 09, 2012

Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose

- Lixisenatide with basal insulin helped type 2 diabetes patients with uncontrolled HbA1c achieve target blood glucose levels -
- Lixisenatide marketing authorization application submitted to European Medicines Agency and U.S. FDA submission expected in Q4 2012 -

 

Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose
- Lixisenatide with basal insulin helped type 2 diabetes patients with uncontrolled HbA1c achieve target blood glucose levels -
- Lixisenatide marketing authorization application submitted to European Medicines Agency and U.S. FDA submission expected in Q4 2012 -

Paris, France – June 9, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c – glycated hemoglobin – in people with type 2 diabetes who were either new to insulin therapy (as early as 12 weeks after initiation) or already treated with insulin (for an average of 3.1 years).